FACBC PET/CT for Recurrent Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2007 |
| End Date: | July 2015 |
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).
Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic
recurrence, and lead to better characterization of disease status in restaging patients.
This is a study that will test a compound (chemical substance) that has a small amount of
radioactivity attached to it. This substance has a natural tendency to go to prostate
tissue. The substance is called [18]FACBC and it is given in the form of an injection into a
vein. After the substance reaches the prostate, scans called PET or Positron Emission
Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound
called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and
cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys
and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if
a growth on the prostate is cancer with scans or x-rays that are usually done.
This study will look at how the [18]FACBC goes into the prostate tissue and determine its
ability to detect recurrent prostate cancer.
recurrence, and lead to better characterization of disease status in restaging patients.
This is a study that will test a compound (chemical substance) that has a small amount of
radioactivity attached to it. This substance has a natural tendency to go to prostate
tissue. The substance is called [18]FACBC and it is given in the form of an injection into a
vein. After the substance reaches the prostate, scans called PET or Positron Emission
Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound
called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and
cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys
and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if
a growth on the prostate is cancer with scans or x-rays that are usually done.
This study will look at how the [18]FACBC goes into the prostate tissue and determine its
ability to detect recurrent prostate cancer.
STUDY NOW CLOSED for recruitment
Inclusion Criteria:
- Patients must be 18 years of age or older.
- Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 )
prostate carcinoma and have undergone what was considered definitive therapy for
localized disease.
- In the case of brachytherapy, cryotherapy, or external beam radiation, treatment will
have occurred at least 2 years in the past to eliminate patients with so-called "PSA
bump."
- Patient will have suspicion of recurrent prostate carcinoma as defined by: ASTRO
criteria of three consecutive rises of PSA or earlier if clinically appropriate,
and/or nadir + 2.0 after radiotherapy, and/or greater than 0.3 after prostatectomy.
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent.
Exclusion Criteria:
- Age less than 18.
- Greater than T3 disease in past
- Prior prostatectomy or 2 years since brachytherapy, cryotherapy, or external beam
radiation therapy.
- Does not meet above criteria of suspicious PSA elevation
- Inability to lie still for PET scanning
- Cannot provide written informed consent.
- Bone scan findings characteristic for metastatic prostate carcinoma
- Less than 2 months since any prior prostate biopsy (to decrease false positive uptake
from inflammation).
We found this trial at
1
site
Emory University Hospital As the largest health care system in Georgia and the only health...
Click here to add this to my saved trials
